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ABSTRACT
Background: Observational studies showed that circulating L-ascorbic
acid (vitamin C) is inversely associated with cardiometabolic traits.
However, these studies were susceptible to confounding and reverse
causation.
Objectives: We assessed the relation between L-ascorbic acid and
10 cardiometabolic traits by using a single nucleotide polymor-
phism in the solute carrier family 23 member 1 (SLC23A1) gene
(rs33972313) associated with circulating L-ascorbic acid concen-
trations. The observed association between rs33972313 and car-
diometabolic outcomes was compared with that expected given
the rs33972313-L-ascorbic acid and L-ascorbic acid–outcome
associations.
Design: A meta-analysis was performed in the following 5 inde-
pendent studies: the British Women’s Heart and Health Study (n =
1833), the MIDSPAN study (n = 1138), the Ten Towns study (n =
1324), the British Regional Heart Study (n = 2521), and the Euro-
pean Prospective Investigation into Cancer (n = 3737).
Results: With the use of a meta-analysis of observational estimates,
inverse associations were shown between L-ascorbic acid and systolic
blood pressure, triglycerides, and the waist-hip ratio [the strongest of
which was the waist-hip ratio (20.13-SD change; 95% CI: 20.20-,
20.07-SD change; P = 0.0001) per SD increase in L-ascorbic acid],
and a positive association was shown with high-density lipoprotein
(HDL) cholesterol. The variation at rs33972313 was associated with
a 0.18-SD (95% CI: 0.10-, 0.25-SD; P = 3.34 3 1026) increase in L-
ascorbic acid per effect allele. There was no evidence of a relation
between the variation at rs33972313 and any cardiometabolic out-
come. Although observed estimates were not statistically different
from expected associations between rs33972313 and cardiometabolic
outcomes, estimates for low-density lipoprotein cholesterol, HDL cho-
lesterol, triglycerides, glucose, and body mass index were in the op-
posite direction to those expected.
Conclusions: The nature of the genetic association exploited in this
study led to limited statistical application, but despite this, when all
cardiometabolic traits were assessed, there was no evidence of any
trend supporting a protective role of L-ascorbic acid. In the context
of existing work, these results add to the suggestion that observa-
tional relations between L-ascorbic acid and cardiometabolic health
may be attributable to confounding and reverse causation. Am J
Clin Nutr 2015;101:202–9.
Keywords L-ascorbic acid, cardiometabolic traits, confounding,
genetic variants, reverse causation
INTRODUCTION
An understanding of the associations between L-ascorbic acid
(vitamin C) and cardiometabolic traits is of particular importance
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to public health because of the potential to modify this
target. However, evidence as to the likely benefit of such an
intervention has been mixed. Several prospective cohort studies
suggested that higher concentrations of circulatory L-ascorbic
acid are associated with a favorable cardiometabolic risk profile.
This profile includes reduced blood pressure, glucose, choles-
terol, and insulin (1–3) and reduced risk of cardiovascular dis-
eases (CVDs)5 and all-cause mortality (4–9).
However, these observational studies may have been biased
because of confounding or suffer reverse causation, whereby an
undiagnosed disease may have influenced dietary intake or cir-
culating concentrations of L-ascorbic acid (10). Therefore, ran-
domized controlled trials (RCTs) were undertaken and provided
some evidence of beneficial effects of L-ascorbic acid supple-
mentation or high dietary intake of fruit and vegetables (natu-
rally high in L-ascorbic acid) on cardiometabolic traits including
LDL cholesterol and HDL cholesterol, triglycerides, insulin,
glucose, and blood pressure (11, 12) and risk of coronary artery
disease and hypertension during follow-up (13–16).
Despite this evidence, other estimates of the causal association
between L-ascorbic acid and cardiometabolic health were not
consistent (17–22). A long-term RCT of vitamin supplementa-
tion on the prevention of CVD in .14,500 men showed that,
after 8 y follow up, there was no evidence that L-ascorbic acid
reduced risk of major cardiometabolic events (HR: 0.99; 95%
CI: 0.89, 1.11; P = 0.91) or CVD mortality (HR: 1.02; 95% CI:
0.85, 1.21; P = 0.86) (18). Similarly, in an RCT of vitamin
supplementation in .8000 women at high risk of CVD, no
overall effects were seen between L-ascorbic acid on later
myocardial infarction, stroke, coronary revascularization, or
CVD death (risk ratio: 1.02; 95% CI: 0.92, 1.13; P = 0.71) (19).
The discovery of the association between the variation at
rs33972313 and circulating L-ascorbic acid (23) provides an
opportunity to use this genetic variant as an instrumental vari-
able (IV) to test putatively causal relations between L-ascorbic
acid and cardiometabolic outcomes (24–27). The aim of this
study was to explore the utility of the variation at the
rs33972313 single nucleotide polymorphism (SNP) to re-
examine potentially causal effects of L-ascorbic acid on a
panel of cardiometabolic traits in a large collection of European
samples.
SUBJECTS AND METHODS
Data from the following 5 independent studies including
18,802 individuals were available: the British Women’s Heart
and Health Study, the MIDSPAN study, the Ten Towns study, the
British Regional Heart Study (BRHS), and the European Pro-
spective Investigation into Cancer (EPIC) study. Related in-
dividuals in the MIDSPAN study were excluded to remove
nonindependent observations. Full details of individual studies,
their ethical approvals, DNA extraction, genotyping, and mea-
surements of L-ascorbic acid concentrations and cardiometabolic
variables were previously published (23) and are provided in the
Supplemental Material. Across the 5 cohorts, 15,959 individuals
had data on both genotype and L-ascorbic acid. In total, full ge-
notypic data and information on L-ascorbic acid and car-
diometabolic outcomes were available for 10,553 participants
from the British Women’s Heart and Health Study (n = 1833),
the MIDSPAN study (n = 1138), the Ten Towns study (n = 1324),
the BRHS (n = 2521), and the EPIC study (n = 3737).
Cardiometabolic outcomes
Eight continuous quantitative traits were shared across the 5
independent studies. Information was available for systolic blood
pressure (SBP; n = 18,449), diastolic blood pressure (DBP; n =
18,449), cholesterol (n = 18,082), HDL cholesterol (n = 17,486),
triglycerides (n = 16,956), glucose (n = 16,550), BMI (n =
18,438), and the waist-hip ratio (WHR; n = 18,410). The re-
maining 2 variables were LDL cholesterol and hypertension.
LDL cholesterol was derived by using Friedewald’s equation for
individuals with triglyceride concentrations ,4 mmol/L (28)
within all 5 cohorts (n = 17,350). Hypertension was defined as
SBP $ 140 mmHg and DBP $ 90 mmHg and used as a binary
outcome.
Genetic variation
We previously showed that the rs33972313 SNP at the solute
carrier family 23 member 1 (SLC23A1) locus, which encodes the
sodium-dependent L-ascorbic acid transporter-1, was reliably
associated with circulating L-ascorbic acid concentrations (23).
The rs33972313 variant exists in European populations with
a minor allele frequency (MAF) w0.06 (merged HapMap
phases I–III, release 28). Each additional minor allele of
rs33972313 was associated with a 5.98-mmol/L (95% CI: 3.73-,
8.23-mmol/L; P = 2.0 3 1027) lower circulating L-ascorbic acid
concentration, and as such, this SNP was selected as a genetic
instrument for circulating L-ascorbic acid in this study. Geno-
typing and appropriate quality control was undertaken with
methods specific to each study (Supplemental Material). Full
genetic information was available for 16,841 individuals from
the 5 studies.
Statistical analysis
All analyses were performed with STATA version 12 software
(StataCorp LP). An inverse rank transformation was used for L-
ascorbic acid and continuous cardiometabolic traits to harmo-
nize data across contributing studies before applied analyses and
take into account systematic differences in the absolute value of
traits because of differing study protocols [as seen previously
(23)]. z scores of transformed continuous traits were generated
to provide per SD effect estimates for the purposes of in-
terpretation. The association between each quantitative trait and
L-ascorbic acid was examined by using linear regression of the
trait z score against L-ascorbic acid z score. The association
between rs33972313 and each quantitative trait (including L-
ascorbic acid) was examined by using a linear regression of the
trait z score against genotype. Logistic regression was used to
investigate associations between both the rs33972313 genotype
and L-ascorbic acid and hypertension risk expressed as ORs.
As each additional minor allele of rs33972313 was asso-
ciated with a decrease in L-ascorbic acid, genotypes at this SNP
were coded in an additive model as 0 (minor homozygotes), 1
5Abbreviations used: CVD, cardiovascular disease; DBP, diastolic blood pres-
sure; EPIC, European Prospective Investigation into Cancer; IV, instrumental vari-
able; MAF, minor allele frequency; MR, Mendelian randomization; RCT,
randomized controlled trial; SBP, systolic blood pressure; SLC23A1, solute carrier
family 23 member 1; SNP, single nucleotide polymorphism;WHR, waist-hip ratio.
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(heterozygotes), and 2 (major homozygotes) to give an L-as-
corbic acid increase per effect allele. Hardy-Weinberg equilib-
rium was tested for rs33972313 with the Stata command genhw.
Meta-analysis
Summary statistics were pooled by using a meta-analysis with
a random-effects model to account for differences between co-
horts and methods (by using the random option for the Stata
command metan). The I2 statistic was used to estimate hetero-
geneity between studies (29). A sensitivity analysis was performed
by excluding subjects known to be taking an antihypertensive
medication.
Calculating expected effect estimates for associations
between SLC23A1 genotype and cardiometabolic outcomes
Despite a relatively strong relation between the variation at
rs33972313 and L-ascorbic acid (which, in isolation, remains the
best instrument for L-ascorbic acid at this locus), the MAF at this
variant was such to preclude the use of a formal IV approach
because of weak instrumentation (as assessed by using an F test
in the first of a 2-stage least-squares analysis) (30, 31). As
a result, a triangulation approach (32) was used to estimate
expected effect estimates (95% CIs) for associations between
the rs33972313 genotype and cardiometabolic outcomes (Fig-
ure 1). Under the assumption that there is a true causal asso-
ciation between L-ascorbic acid and each cardiometabolic
outcome, and because rs33972313 had an independent associ-
ation with L-ascorbic acid, it was predicted that the SLC23A1-
outcome association (Figure 1C) would be proportional to the
relation of both the SLC23A1–L-ascorbic acid association (Fig-
ure 1A) and each L-ascorbic acid–outcome association (Figure
1B) (Supplemental Material). The method assumes that the
portion of variance explained in L-ascorbic acid by rs33972313
is independent of other factors, and therefore, the genetic variant
provides an unconfounded instrument for L-ascorbic acid that is
not susceptible to reverse causation.
To generate the expected SD change in each cardiometabolic
trait per SD increase in L-ascorbic acid, the effect estimate of
each L-ascorbic acid–trait association was multiplied by the
magnitude of the effect of rs33972313 on L-ascorbic acid. SEs
for expected estimates were calculated by using the Taylor series
expansion of the product of observed and expected estimates
(33). Expected ORs and SEs for hypertension risk were calcu-
lated by using the same method on the log(OR) scale and back
transformed onto the OR scale by exponentiating calculated
expected estimates. Observed and expected estimates for each
SLC23A1-outcome association were compared by using the meth-
odology previously reported (32) (Supplemental Material). If the test
of the comparison of observed and expected associations gave
evidence of a statistical difference between effect estimates (P ,
0.05), this result provided no evidence of a causal association be-
tween L-ascorbic acid and the cardiovascular outcome. To assess
the causal association, cardiometabolic outcomes were ana-
lyzed individually and in combination.
RESULTS
Mean (6SD) L-ascorbic acid concentrations ranged between
30.21 6 27.55 mmol/L in the BRHS to 52.70 6 20.40 mmol/L
in the EPIC study (Table 1). Summary statistics of all car-
diometabolic traits and the prevalence of hypertension are pre-
sented in Table 1. Across all studies, rs33972313 was observed
at an average MAF of 0.04 with no overall departure from the
Hardy-Weinberg equilibrium within all studies except the
MIDSPAN study (P = 0.0002) (Table 2).
Association between SLC23A1 and L-ascorbic acid
A pooled analysis of the relation between rs33972313 and
circulating L-ascorbic acid concentrations showed a 0.23-SD
(95% CI: 0.12-, 0.35-SD; P = 8.26 3 1025) increase in L-ascorbic
acid per effect allele. Consistent with results previously reported
(23), there was a high level of heterogeneity in the meta-analysis
of all studies (I2: 71.9%; 95% CI: 29%, 89%; P = 0.007)
(Supplemental Figure S1), which was reduced only by the
exclusion of the EPIC study (I2 = 0%; P = 0.99). Because of this
result and to allow for additional applied analyses, the EPIC
study was removed from main analyses and treated as an in-
dependent replication study (although random-effects models
were still used, and sensitivity meta-analyses were undertaken
that included the EPIC study).
The meta-analysis with the exclusion of the EPIC study
showed a 0.18-SD (95% CI: 0.10-, 0.25-SD; P = 3.34 3 1026)
increase in L-ascorbic acid per effect allele (Table 3, Supple-
mental Figure S2). Within the EPIC study, each additional effect
allele was associated with a 0.40-SD (95% CI: 0.31-, 0.50-SD;
P = 2.73 3 10217) increase in L-ascorbic acid (Table 3).
Associations between L-ascorbic acid and cardiometabolic
outcomes and confounders
Meta-analyses of observational estimates suggested that circu-
lating concentrations of L-ascorbic acid were inversely associated
with SBP, triglycerides, and the WHR (Table 4, Supplemental
Figures S3 and S4), the strongest of which was the WHR [20.13-
SD change (95% CI: 20.20-, 20.07-SD change; P = 0.0001) per
SD increase in L-ascorbic acid]. There was also evidence of
a positive association between L-ascorbic acid and HDL cholesterol
(Table 4, Supplemental Figures S3 and S4). Within the EPIC study,
there were strong inverse associations between L-ascorbic acid and
FIGURE 1 Triangulation approach used to estimate the effect size of the
SLC23A1-cardiometabolic outcome association (C) given the association be-
tween SLC23A1 and L-ascorbic acid (A) and observed associations between L-
ascorbic acid and the outcomes (B). We hypothesized that associations observed
between the SLC23A1 genotype and cardiometabolic outcomes (dotted line)
would be mediated by L-ascorbic acid (i.e., C = A 3 B; solid lines). Therefore,
effect estimates should be expected to reflect both the SLC23A1–L-ascorbic
acid association and L-ascorbic acid–cardiometabolic outcome associations.
SLC23A1, solute carrier family 23 member 1.
204 WADE ET AL.
SBP, DBP, cholesterol, LDL cholesterol, triglycerides, glucose,
BMI, and the WHR and a positive association between L-ascorbic
acid and HDL cholesterol (Supplemental Table S1). The OR for
hypertension risk was 0.75 (95% CI: 0.71, 0.80; P = 2.483 10221)
per SD increase in L-ascorbic acid. The inclusion of the EPIC study
within meta-analyses gave similar results (Supplemental Figure
S5). In meta-analyses of observational estimates, there was evi-
dence of heterogeneity (all I2 . 60%) (Table 4, Supplemental
Figure S4).
Across all studies, L-ascorbic acid was associated with smoking
status, alcohol intake, physical activity, and socioeconomic position
alongside obesity, insulin, C-reactive protein, IL-6, and urate
(where available) (Supplemental Table S2). Adjustment for po-
tentially confounding factors including age, sex (where appropri-
ate), smoking and alcohol use, physical activity, and measures of
socioeconomic position made little difference to observational as-
sociations (results available from authors upon request).
Association between SLC23A1 and cardiometabolic
outcomes and confounders
Meta-analyses from 4 studies of the observed change in
cardiometabolic outcomes per effect allele showed no substantive
evidence for an association between rs33972313 and any car-
diometabolic outcome (Table 5, Supplemental Figures S6 and
S7). There was little evidence of between-study heterogeneity
for a majority of the cardiometabolic outcomes [I2# 15% for all
cardiometabolic outcomes except HDL (39.2%) and triglycerides
(64%)]. Within the EPIC study, there were no associations
between any of the cardiometabolic outcomes and rs33972313
(Supplemental Table S3), and the inclusion of the EPIC study
within the meta-analysis gave results consistent with those of the
main analysis (Supplemental Figure S8), but heterogeneity was
introduced. Across all cohorts, rs33972313 was not associated
with any of the potentially confounding factors (Supplemental
Table S4).
Comparison between observed and expected effect
estimates
The comparison of observed and expected associations be-
tween rs33972313 and cardiometabolic traits yielded no sub-
stantive evidence of a difference between the 2 sets of results
(P-comparison values of observed and expected effect estimates
ranged between 0.13 and 0.88) (Table 5, Figure 2). However,
along with the widening of CIs to include the null, observed
TABLE 1
Descriptive characteristics for each of the included cohorts1
BWHHS (n = 4286) MIDSPAN (n = 1477) Ten Towns (n = 1531) BRHS (n = 3945) EPIC (n = 7563)
Variables n Values n Values n Values n Values n Values
Women, % 4286 100 1477 54.91 1531 44.74 3945 0 7563 50.64
Age, y 4284 68.88 6 5.512 1477 45.39 6 6.04 1531 15.06 6 0.58 3945 68.74 6 5.49 7563 59.50 6 9.22
L-ascorbic acid, mmol/L 3606 43.25 6 28.04 1364 49.20 6 25.27 1531 50.36 6 23.92 3811 30.21 6 27.55 7106 52.70 6 20.40
SBP, mm Hg 3964 147.13 6 25.23 1464 127.53 6 15.69 1527 120.82 6 12.96 3942 142.78 6 19.56 7552 136.08 6 18.25
DBP, mm Hg 3964 79.39 6 11.66 1464 74.75 6 11.17 1527 66.91 6 7.34 3942 81.42 6 12.80 7552 83.00 6 11.16
WHR 3946 0.82 6 0.07 1462 0.84 6 0.09 1528 0.76 6 0.06 3918 0.95 6 0.06 7556 0.86 6 0.09
BMI, kg/m2 3957 27.62 6 5.01 1467 26.19 6 4.52 1525 20.93 6 3.64 3926 26.88 6 3.68 7563 26.48 6 3.90
Cholesterol, mmol/L 3851 6.64 6 1.21 1452 5.29 6 0.97 1523 4.22 6 0.72 3927 6.31 6 1.03 7329 6.18 6 1.18
Glucose, mmol/L 3829 6.06 6 1.66 1454 5.35 6 1.54 1500 5.09 6 0.81 3925 5.56 6 1.25 5842 4.51 6 2.22
HDL cholesterol, mmol/L 3845 1.66 6 0.45 1279 1.42 6 0.37 1523 1.45 6 0.30 3813 1.15 6 0.25 7026 1.40 6 0.42
LDL cholesterol,3 mmol/L 3762 4.14 6 1.09 1276 3.20 6 0.87 1523 2.32 6 0.62 3832 3.90 6 0.98 6957 3.65 6 1.04
Triglycerides, mmol/L 3851 1.87 6 1.19 1448 1.60 6 1.26 1523 1.01 6 0.41 2805 2.03 6 1.29 7329 1.89 6 1.15
Prevalent hypertension4 2226 30.14 1477 13.20 1404 0.28 3942 53.53 6062 28.04
1BRHS, British Regional Heart Study; BWHHS, British Women’s Heart and Health Study; DBP, diastolic blood pressure; EPIC, European Prospective
Investigation into Cancer; SBP, systolic blood pressure; WHR, waist-hip ratio.
2Mean 6 SD (all such values).
3Derived by using Friedewald’s equation (with the exclusion of individuals with triglyceride concentrations $4 mmol/L) (28).
4Hypertension was defined as SBP $ 140 mm Hg and DBP $ 90 mm Hg.
TABLE 2
SNP description showing genotypic frequencies, MAF, and HapMap figures of MAF for rs339723131
Genotype frequencies, %
Study n
Minor
homozygote (AA)
Heterozygote
(AG)
Major
homozygote (GG) MAF
Hardy-Weinberg
equilibrium P HapMap
BWHHS 3719 0.16 6.29 93.55 0.03 0.30 0.06
MIDSPAN 1379 0.73 7.32 91.95 0.04 0.0002
Ten Towns 1477 0.14 6.77 93.09 0.04 0.70
BRHS 3870 0.10 6.64 93.26 0.03 0.79
EPIC 6396 0.16 6.93 92.92 0.04 0.59
1BRHS, British Regional Heart Study; BWHHS, British Women’s Heart and Health Study; EPIC, European Pro-
spective Investigation into Cancer; MAF, minor allele frequency; SNP; single nucleotide polymorphism.
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point estimates for HDL cholesterol, LDL cholesterol, triglycerides,
glucose, and BMI were in the opposite direction to those expected
(Table 5).
The exclusion of individuals who were known to be on lipid-
lowering or antihypertensive medication had no substantive ef-
fect on results (Supplemental Tables S5 and S6). Within the
EPIC study, results were consistent (Supplemental Table S3),
and the inclusion of the EPIC study within the meta-analysis
also showed consistent patterns but inflated the level of het-
erogeneity (Supplemental Table S7, Supplemental Figure S9).
DISCUSSION
This study attempted to exploit the association between the
SLC23A1 and L-ascorbic acid to provide a more-reliable estimate of
the causal relation between L-ascorbic acid and cardiometabolic
health without the limitations present in observational analyses,
including reverse causation and confounding.
The observational examination of the relation between L-ascorbic
acid concentrations and a collection of cardiometabolic out-
comes showed inverse associations between SBP, triglycerides,
and the WHR and a positive association with HDL cholesterol.
Despite these results, although comparisons between observed
and expected effect estimates for the impact of L-ascorbic acid
were limited by power, estimates were not suggestive of a causal
effect. Taken together, when observed and expected associa-
tions between L-ascorbic acid and cardiometabolic outcomes
across all traits were compared, there was no suggestion of
trend, and if anything, point estimates appeared discordant.
Although results were not definitive, in the context of existing
work (34), these findings add to the growing evidence suggesting
that L-ascorbic acid is an unlikely causal factor in the improve-
ment of cardiometabolic health and suggest that observational
associations may be explained by confounding or reverse causa-
tion (34, 35).
As to why observational estimates may indicate a beneficial
effect of L-ascorbic acid, L-ascorbic acid may be a marker of
particular foods and lifestyles, which are genuine risk factors for
disease (18, 20, 35, 36). For example, individuals who are more
physically active and smoke less may also have high concen-
trations of circulating L-ascorbic acid as a result or indicator of
the healthy lifestyle they lead, which itself is beneficial to car-
diometabolic health, as opposed to L-ascorbic acid directly. To
this end, these results are in agreement with those of a recent
meta-analysis of 20 RCTs (n = 294,478), which gave no evi-
dence to support that antioxidant vitamin supplementation has
an effect on the incidence of major cardiometabolic events (37).
Therewere a number of limitations to the current investigation.
There was a high level of heterogeneity in the meta-analysis of
observational results, which was likely attributable to differences
between study protocols and effect estimates. This outcome was
indicative of the complications encountered when trying to
formulate reliable observational estimates and is in stark contrast
to the consistency of genetic data and relations between variation
at SLC23A1 and L-ascorbic acid. This result also highlights the
need for alternative approaches, such as the method used in the
current study, which lever value out of genetic data in applied
epidemiologic analyses to obtain unconfounded and unbiased
causal estimates, which seek to add to the weight of evidence.
Furthermore, the use of discovery samples in an applied
TABLE 3
Associations between rs33972313 and L-ascorbic acid in the 4 included studies (n = 9946)1
L-ascorbic acid per allele variation, mmol/L
Study n
Minor
homozygote (AA)
Heterozygote
(AG)
Major
homozygote (GG)
Per allele effect on
standardized L-ascorbic acid P
Variance explained
by SNP, %
BWHHS 3438 52.61 (17.94, 87.28)2 38.61 (35.07, 42.14) 43.69 (42.72, 44.66) 0.17 (0.04, 0.30) 0.01 0.19
MIDSPAN 1291 39.30 (24.08, 54.52) 45.02 (40.63, 49.42) 49.68 (48.22, 51.14) 0.16 (20.01, 0.34) 0.07 0.40
Ten Towns 1477 64.0 (2520.49, 648.49) 44.86 (40.99, 48.73) 50.64 (49.36, 51.92) 0.20 (0.01, 0.40) 0.04 0.28
BRHS 3740 21.53 (6.43, 36.62) 27.55 (24.25, 30.85) 30.31 (29.41, 31.21) 0.18 (0.05, 0.30) 0.01 0.21
Meta-analysis 9946 33.35 (19.70, 46.99) 38.94 (30.55, 47.34) 43.57 (33.77, 53.37) 0.18 (0.10, 0.25) 3.34 3 1026 0.28
EPIC 6013 36.50 (27.24, 45.76) 46.63 (45.06, 48.20) 54.74 (54.21, 55.28) 0.40 (0.31, 0.50) 2.73 3 10217 1.18
1BRHS, British Regional Heart Study; BWHHS, British Women’s Heart and Health Study; EPIC, European Prospective Investigation into Cancer; SNP,
single nucleotide polymorphism.
2Mean; 95% CI in parentheses (all such values).
TABLE 4
Meta-analysis of associations of L-ascorbic acid with cardiometabolic
outcomes within 4 cohorts1
Phenotype n
Observed change in outcome per
SD change in L-ascorbic acid2 P I2, %
SBP 10,274 20.06 (20.10, 20.02) 0.002 70.0
DBP 10,274 20.05 (20.13, 0.02) 0.14 92.5
Cholesterol 10,247 20.001 (20.05, 0.04) 0.95 78.8
HDL cholesterol 9985 0.06 (0.0003, 0.12) 0.05 88.9
LDL cholesterol 9936 0.005 (20.04, 0.05) 0.82 76.5
Triglycerides 9146 20.09 (20.16, 20.02) 0.02 91.7
Glucose 10,202 20.04 (20.09, 0.01) 0.12 82.9
BMI 10,224 20.05 (20.11, 0.01) 0.09 88.9
WHR 10,236 20.13 (20.20, 20.07) 0.0001 91.2
Hypertension3 8592 0.93 (0.83, 1.03) 0.17 63.2
1P values are from a random-effects meta-analysis of linear regression
coefficients estimated within each study for each phenotype z score (on the
inverse rank scale) against L-ascorbic acid z score (inverse rank scale). I2 is
the percentage of the total variance in study estimates that was attributable to
between-study heterogeneity (29). DBP, diastolic blood pressure; SBP, sys-
tolic blood pressure; WHR, waist-hip ratio
2All values are means; 95% CIs in parentheses. Values are for effect
sizes per SD increase in L-ascorbic acid and meta-analysis P values. All
continuous traits were inverse-rank transformed before calculation of the
z score.
3Estimates were calculated on the log(OR) scale and exponentiated to
give an expected OR estimate for hypertension risk.
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Mendelian randomization (MR) analysis can potentially yield
overfitting (38).
Exploratory IV analyses gave first-stage F statistics that were
either marginal or did not greatly exceed an acceptable threshold
to justify the appropriate application of this method for the
generation of MR estimates (31). Therefore, it would have been
inappropriate to perform an IV analysis in this context because
of the use of the collection used in the current study in the
TABLE 5
Meta-analysis of associations of cardiometabolic outcomes with rs33972313 and with L-ascorbic acid within 4 cohorts1
Phenotype n
Change in outcome z score per effect allele2
P-rs33972313 association
with outcome3 I2, %
P-difference between
observed and expectedExpected Observed
SBP 10,402 20.01 (20.02, 20.003) 20.02 (20.09, 0.06) 0.63 0 0.84
DBP 10,402 20.01 (20.02, 0.004) 20.02 (20.09, 0.05) 0.56 0 0.75
Cholesterol 10,362 20.0002 (20.01, 0.01) 20.03 (20.10, 0.04) 0.44 0 0.45
HDL cholesterol 10,083 0.01 (20.0005, 0.02) 20.06 (20.16, 0.04) 0.21 39.2 0.13
LDL cholesterol 10,019 0.001 (20.01, 0.01) 20.04 (20.11, 0.03) 0.28 0 0.27
Triglycerides 9257 20.02 (20.03, 20.002) 0.09 (20.05, 0.22) 0.21 64.0 0.13
Glucose 10,321 20.01 (20.02, 0.003) 0.03 (20.04, 0.10) 0.43 0 0.30
BMI 10,377 20.01 (20.02, 0.001) 0.01 (20.07, 0.09) 0.88 15.0 0.72
WHR 10,355 20.02 (20.04, 20.01) 20.02 (20.09, 0.06) 0.67 0 0.84
Hypertension4 8580 0.99 (0.97, 1.01) 0.97 (0.76, 1.24) 0.80 0 0.88
1All continuous traits are inverse-rank transformed before calculation of z score. All effect sizes (95% CIs) are presented in SD units. I2 is the percentage of total
variance in study estimates that is attributable to between-study heterogeneity (29). DBP, diastolic blood pressure; SBP, systolic blood pressure; WHR, waist-hip ratio.
2All values are means; 95% CIs in parentheses. Values are for observed and expected effect sizes and meta-analysis P values.
3Values are from a random-effects meta-analysis of linear regression coefficients estimated within each study for each phenotype z score (on the inverse
rank scale) against rs33972313 genotype.
4Estimates for hypertension were calculated on the log(OR) scale and exponentiated to give an expected OR estimate for hypertension risk.
FIGURE 2 Observed compared with expected effects (95% CIs) of the SLC23A1 allele on each cardiometabolic trait. Observed effect estimates per
SLC23A1 allele for each cardiometabolic trait are plotted against expected effect estimates given the SLC23A1–L-ascorbic acid effect estimate and observed L-
ascorbic acid–trait associations. Colors refer to each cardiometabolic trait. DBP, diastolic blood pressure; SBP, systolic blood pressure; SLC23A1, solute
carrier family 23 member 1; WHR, waist-hip ratio.
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discovery of the SNP–L-ascorbic acid relation (23). As the fre-
quency of each minor allele of rs33972313 wasw4% within the
current sample, there was also limited statistical power. Al-
though the observed effect of rs33972313 on circulating con-
centrations of L-ascorbic acid was relatively large, the rareness
of this variant effectively limited the population-based variance
explained in L-ascorbic acid and, thus, impeded our ability to
draw firm causal inference [as shown elsewhere (39)]. Despite
this, rs33972313 remains the best available instrument for the
application of this type of analysis.
In conclusion, in the absence of appropriate conditions to
undertake a formal MR analysis, the application of the tri-
angulation approach by using a genetic proxy for circulating
concentrations of L-ascorbic acid was unable to provide de-
finitive evidence to clarify the causal role of L-ascorbic acid on
cardiometabolic health. Results suggest that a larger homoge-
nous study of the impact of circulating L-ascorbic acid should be
undertaken by using this design. In the absence of such a study,
the current results add to the growing evidence against a likely
beneficial role for L-ascorbic acid supplementation in otherwise
healthy individuals.
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